[ TRANSACTION RECORD ]

AbbVie Inc. Investment in AbbVie ImmunoGen Platform — 2023

VERIFIED VECTOR ID: 002215 · tx-311
M SOURCE NODE — FUNDER
AbbVie Inc.
Healthcare United States
$10,100,000,000
EQUITY
30/11/2023
Q DESTINATION NODE — RECIPIENT
AbbVie ImmunoGen Platform
SPV United States
Amount (USD)
$10.1B
Flow Type
EQUITY
Transaction Date
30/11/2023
Primary Source
View Filing ↗
Funder Profile [ M ]
Entity AbbVie Inc.
AUM 300000
HQ Location United States
Sector Healthcare
Recipient Profile [ Q ]
Entity AbbVie ImmunoGen Platform
Entity Type SPV
Jurisdiction United States
Intelligence Note

AbbVie Inc. announced the acquisition of ImmunoGen for 10.1 billion dollars to strengthen its oncology portfolio with a leading targeted antibody-drug conjugate for cancer treatment. This transaction provide AbbVie with a commercially available therapy for ovarian cancer patients globally. This deal represents a significant institutional healthcare investment in the next generation of medicine.

Σ
Primary Forensic Source https://news.abbvie.com/2023-11-30-AbbVie-to-Acquire-ImmunoGen/
✓ SOURCE LINKED